
Home / Clinics Supported / Hormone Optimization / Women's Health
The menopause conversation has reached the mainstream, and many markets still have no dedicated women's hormone clinic. ACG helps you open the one that should have been there years ago. No medical background is required to own the business; an independent, state-licensed Medical Director directs all clinical care.
Book a Strategy CallU.S. searches for “menopause treatment” run 1,000 to 10,000 a month (Google Keyword Planner). In February 2026 the FDA approved the first label changes removing the boxed-warning risk statements on cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy, after asking 29 drug companies to revise their labels.
Many markets have no dedicated women's hormone clinic answering these searches locally. Our wellness clinic launch program helps you open one, with no franchise royalties.
She is looking for a clinic that monitors her and adjusts with her over time, not a 15-minute appointment and a prescription. That relationship drives lifetime value in women's hormone care.
Monthly U.S. searches, Google Keyword Planner, Sep 2025 to Aug 2026, in the ranges Google reports. “HRT for women” returns no figure, as Google withholds some health terms. Local demand varies by market.
Hormone care at the core, with the adjacent services that keep patients enrolled.
Estradiol, progesterone and testosterone, prescribed by your Medical Director from FDA-approved products or vetted 503A compounding pharmacies. The anchor of women's hormone care.
Hormone panels, symptom tracking and protocol adjustment from perimenopause through post-menopause.
Sermorelin, prescriber-directed, is the defensible adjunct alongside BHRT. CJC-1295 and ipamorelin, the two patients read about, cannot be compounded today (October 2026). See the peptide therapy status table.
Libido and intimacy support within the BHRT relationship, including PRP-based procedures under generic names: several branded protocol names in this space are registered trademarks that require licensing.
Body composition and metabolic panels, with FDA-approved GLP-1s for the patient whose weight changes through menopause, as in a medical weight loss clinic.
Ongoing labs and quarterly check-ins that sustain the patient relationship and the recurring revenue behind it.
Many products marketed as bioidentical hormones are compounded drugs, which the FDA says are not FDA-approved, so pharmacy vetting, prescribing structure and Medical Director oversight decide how a clinic offers them. Prescribing authority varies by state.
Branded procedure names are a live exposure in this category: several are registered trademarks, so ACG writes your service descriptions in generic clinical language unless you hold the license.
Pre-vetted compounding pharmacy partners for estradiol, progesterone and testosterone at preferred pricing.
Vetted MDs with experience in women's hormone health, through partner networks covering all 50 states. ACG coordinates the supervision agreement.
Intake, informed consent and clinical protocols, set with your Medical Director before your first patient.
Service names and procedure descriptions checked against trademarks and platform ad rules before anything goes live. ACG plans the marketing strategy; execution is a separate engagement.
60 days of post-launch advisory on patient flow, operations and marketing strategy.
Straight answers on services, BHRT compliance, branded procedure names, prescribers, telehealth and pricing. Anything else, ask on the strategy call.
View All FAQs
Your market may be waiting for a women's hormone clinic. Talk with Grayson Miller about local demand, BHRT compliance and what opening takes. No pitch. No obligation.
ACG is a consulting and advisory firm, not a medical practice; an independent, state-licensed Medical Director directs all clinical care. Results are not guarantees of income. Individual outcomes vary. The 60-day target begins from clinic keys received, market and regulatory conditions permitting.
Knowing the rules is the foundation of every clinic we help launch.
You own and run the business. An independent, state-licensed Medical Director makes every clinical, prescribing and treatment decision, structured for your state's Corporate Practice of Medicine laws. We connect you to a vetted network; you retain your own provider.
PRP, peptides, GLP-1 medications and cellular products each carry federal and state rules, and not every product or use is FDA-approved. Exosomes for therapeutic use are not FDA-approved at all, and we steer you away from them. Your menu and marketing are built to hold up to FDA, FTC and state medical board scrutiny.
We show real ranges and never promise an income or a clinical outcome. What you earn depends on your market, your capital and your execution.
Altos Consulting Group is a business consulting and advisory firm, not a medical practice, and does not provide, prescribe or sell any drug, biologic, device or therapy. The FDA has stated there are currently no FDA-approved exosome products for the treatment of any disease; clinic owners are responsible for the compliance of every product, therapy and claim. See the full regulatory notice below.